专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11597731B2 Process for preparing highly pure temozolomide 有权
公开(公告)号：US11597731B2
公开(公告)日：2023-03-07
申请号：US17378663
申请日：2021-07-17
申请人： Akshay Kant Chaturvedi , Bijan Kumar Panda , Amit Kumar , Deepali Chaturvedi
发明人： Akshay Kant Chaturvedi , Bijan Kumar Panda , Amit Kumar , Deepali Chaturvedi
IPC分类号： C07D259/00 , C07D487/04 , C07C273/18
摘要： The present invention provides a new process for preparation of imidazo-tetrazine class of chemical entity useful as anticancer agent. The present invention provides a commercially and economically viable process for preparation of Temozolomide of formula (VI). Present invention also relates to an intermediate compound of formula (III) and its preparation useful in the process for preparing Temozolomide.

2. 发明公开

US20240327374A1 LENALIDOMIDE PROCESS 审中-公开
公开(公告)号：US20240327374A1
公开(公告)日：2024-10-03
申请号：US18129074
申请日：2023-03-31
申请人： Akshay Kant Chaturvedi , Mohammad Baqer , Bijan Kumar Panda , Satyaveer , Deepali Chaturvedi , Saroj Bala , Yogesh Tripathi
发明人： Akshay Kant Chaturvedi , Mohammad Baqer , Bijan Kumar Panda , Satyaveer , Deepali Chaturvedi , Saroj Bala , Yogesh Tripathi
IPC分类号： C07D401/04
CPC分类号： C07D401/04 , C07B2200/13
摘要： The present invention provides to an improved process for the preparation of new and high purity crystalline Form SRA of 3-(4-amino-1-oxoisoindolin-2-yl) piperidine-2, 6-dione of formula (I)

The pure crystalline Form SRA of compound of formula (I) obtained by the process of present invention is having purity of greater than 99.9% (area % by HPLC).
Lenalidomide (I) pure crystalline Form SRA is useful in the treatment of cancer, inflammatory diseases, autoimmune diseases and Multiple myeloma.

3. 发明授权

US09217001B2 Crystalline bortezomib process 有权
标题翻译：结晶硼替佐米方法
公开(公告)号：US09217001B2
公开(公告)日：2015-12-22
申请号：US14434105
申请日：2013-11-12
申请人： Vimal Kumar Shrawat , Rafiuddin , Vinod Kumar Singh , Akshay Kant Chaturvedi
发明人： Vimal Kumar Shrawat , Rafiuddin , Vinod Kumar Singh , Akshay Kant Chaturvedi
IPC分类号： C07D241/12 , C07F5/02 , C07F5/04
CPC分类号： C07F5/025 , C07B2200/13 , C07D241/12
摘要： The present invention provides process for preparation of crystalline Bortezomib (Ia) as its monohydrate which is designated as crystalline Form-SB and characterized by having water content ranging between 3.5-6.0% w/w; X-ray powder diffraction pattern comprising characteristic 2θ° peaks selected from the XRPD peak set of 5.6, 7.5, 9.8, 10.2, 11.3, 15.1, 18.0, 20.5, 21.5 and 23.6±0.20 2θ°, wherein peaks at 9.8 and 11.39±0.20 2θ° are un-split and 100% intensity peak is present at 5.6±0.20 2θ°, DSC isotherm comprising the endothermic peaks ranging between 45 to 60° C. (Peak-1) and 175 to 185° C. (Peak-2) and IR absorption characteristic peaks approximately at 3387 cm−1, 3304 cm−1, 2953 cm−1, 2927 cm−1, 2868 cm−1, 1627 cm−1, 1455 cm−1, 1400 cm−1, 1201 cm−1, 1150 cm−1, 1020 cm−1, 747 cm−1 and 702 cm−1 and Raman absorption spectra having characteristic peaks approximately at 3066 cm−1, 1583 cm−1, 1528 cm−1, 1281 cm−1, 1213 cm−1, 1035 cm−1, 1022 cm−1 and 1004 cm−1. The invention also provides the use of said crystalline Form-SB as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of cancer.
摘要翻译：本发明提供制备作为其一水合物的结晶硼替佐米（Ia）的方法，其被称为结晶形式-SB，其特征在于含水量在3.5-6.0％w / w之间; X射线粉末衍射图包含特征2＆amp; t s;峰值选自5.6,7.5,9.8,10.2,11.3,15.1,18.0,20.5,21.5和23.6±0.20 2的色度;°，其中9.8和11.39的峰 ±0.20 2＆amp; thetas;°是未分裂的，并且在5.6±0.20 2时存在100％强度峰值;°，DSC等温线包含在45至60℃（峰-1）和175至185℃之间的吸热峰。（峰-2）和IR吸收特征峰值大约在3387cm -1，3304cm -1，2953cm -1，2927cm -1，2868cm -1，1627cm -1，1455cm -1，1400cm -1，具有大约在3066cm-1,1583cm-1,1528cm -1的特征峰的拉曼吸收光谱的1,1201cm -1，1150cm -1，1020cm -1，747cm -1和702cm -1， 1281cm-1,1213cm-1,1035cm -1，1022cm -1和1004cm -1。本发明还提供所述结晶形式-SB作为药物组合物中的活性药物成分用于治疗癌症的用途。

4. 发明授权

US11518733B2 Process for preparation of highly pure Fingolimod hydrochloride 有权
公开(公告)号：US11518733B2
公开(公告)日：2022-12-06
申请号：US17468722
申请日：2021-09-08
申请人： Akshay Kant Chaturvedi , Vimal Kumar Shrawat , Sahdev Singh
发明人： Akshay Kant Chaturvedi , Vimal Kumar Shrawat , Sahdev Singh
IPC分类号： C07C213/02 , C07C213/10 , C07C231/12
摘要： The present invention provides process for preparation of highly pure Fingolimod hydrochloride (I), without involving the use of column chromatographic purification in the entire process. Fingolimod hydrochloride (I) obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式